From Breakthrough to Maturity: How Cell Therapy Is Evolving
Cell therapy has come a long way in just over a decade. What began as...
Why Vaccines Still Matter: Valneva CEO Thomas Lingelbach on Science, Politics, and the Future of Vaccine Innovation
Few areas of healthcare have saved more lives, or generated more debate, than vaccines. For...
Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50
Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro...
Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49
Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are...
From Make-or-Break to Record-Breaking: How One Phase 3 Readout Delivered the Biggest Biotech Stock Surge in NASDAQ History
In biotech, Phase 3 data can change everything, or end everything. Few stories capture that...
Free Database of the Top 100 Public Biotechs in Europe
The FlotBio Map is live at map.flot.bio 🙌 Here’s a bit of background FlotBio Map...
Why AI in Biopharma Didn’t Live Up to the Hype
AI has reshaped entire industries, from software development to entertainment, yet its impact in healthcare...
Werner Lanthaler 🇦🇹 | Biopharma AI, CDMO, Antibody Optimization | E48
Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and...
Thomas Lingelbach, Valneva | Vaccines, Lyme Disease | E47
Valneva now has three commercialized vaccines and a Lyme disease candidate in Phase 3. Philip...
Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46
When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge...
Never Miss a New Episode 💌
Trusted by 2500+ biopharma professionals from top companies like argenx, Roche, and Forbion. No spam, no noise.
Watch & Subscribe
